Advanced Chronic Kidney Disease is a Strong Predictor of Hypogonadism and is Associated with Decreased Lean Tissue Mass

References

• EAU Guidelines on Male Hypogonadism. Edn Presented at the EAU Annual Congress Barcelona 2019. EAU Guidelines Office:Arnhem, The Nederlands.
   Google Scholar
• Hall SA, Esche GR, Araujo AB, et al. Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J Clin Endocrinol Metab. 2008;93(10):3870‐3877. doi:10.1210/jc.2008-0021.
   Web of Science ®Google Scholar
• Carrero JJ, Stenvinkel P. The vulnerable man: impact of testosterone deficiency on the uraemic phenotype. Nephrol Dialysis Transplant. 2012;27(11):4030–4041. doi:10.1093/ndt/gfs383.
   Web of Science ®Google Scholar
• Thirumavalavan N, Wilken NA, Ramasamy R. Hypogonadism and renal failure: an update. Indian J Urol. 2015;31(2):89–93. doi:10.4103/0970-1591.15429725878406
   PubMedGoogle Scholar
• Reinhardt W, Kübber H, Dolff S, Benson S, Führer D, Tan S. Rapid recovery of hypogonadism in male patients with end stage renal disease after renal transplantation. Endocrine. 2018;60(1):159‐166. doi:doi:10.1007/s12020-018-1543-2
   Web of Science ®Google Scholar
• Fugl-Meyer KS, Nilsson M, Hylander B, Lehtihet M. Sexual function and testosterone level in men with conservatively treated chronic kidney disease. Am J Mens Health. 2017;11(4):1069‐1076. doi:10.1177/1557988317703207
   Web of Science ®Google Scholar
• Cobo G, Gallar P, Di Gioia C, et al. Hypogonadism associated with muscle atrophy, physical inactivity and ESA hyporesponsiveness in men undergoing haemodialysis. Nefrologia. 2017;37(1):54‐60. doi:10.1016/j.nefro.2016.04.009
   Web of Science ®Google Scholar
• Khurana KK, Navaneethan SD, Arrigain S, Schold JD, Nally JV Jr, Shoskes DA. Serum testosterone levels and mortality in men with CKD stages 3-4. Am J Kidney Dis. 2014;64(3):367‐374. doi:10.1053/j.ajkd.2014.03.010
   Web of Science ®Google Scholar
• Zdravevski E, Lameski P, Kulakov A, Weight of evidence as a tool for attribute transformation in the preprocessing stage of supervised learning algorithms. The 2011 International Joint Conference on Neural Networks, San Jose, CA; 2011: 181–188. doi:10.1109/IJCNN.2011.6033219.
   Google Scholar
• Listen data. Weight Of Evidence (WOE) and Information Value (IV) explained Available from: https://www.listendata.com/2015/03/weight-of-evidence-woe-and-information.html. Accessed 722, 2020.
   Google Scholar
• Wu FC, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008;93(7):2737‐2745. doi:10.1210/jc.2007-1972
   Web of Science ®Google Scholar
• Carrero JJ, Kyriazis J, Sonmez A, et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol. 2012;7(2):207‐215. doi:10.2215/CJN.06840711
   Web of Science ®Google Scholar
• Yilmaz MI, Sonmez A, Qureshi AR, et al. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(7):1617‐1625. doi:10.2215/CJN.10681210
   Web of Science ®Google Scholar
• Edey MM. Male sexual dysfunction and chronic kidney disease. Front Med (Lausanne). 2017;4:32. doi:10.3389/fmed.2017.0003228382300
   PubMed Web of Science ®Google Scholar
• Dousdampanis P, Trigka K, Fourtounas C. Hypomagnesemia, chronic kidney disease and cardiovascular mortality: pronounced association but unproven causation. Hemodial Int. 2014;18(4):730‐739. doi:10.1111/hdi.12159
   Web of Science ®Google Scholar
• Hylander B, Lehtihet M. Testosterone and gonadotropins but not SHBG vary with CKD stages in young and middle aged men. Basic Clin Androl. 2015;25:9. doi:10.1186/s12610-015-0027-y26635963
   PubMedGoogle Scholar
• Rymarz A, Bartoszewicz Z, Szamotulska K, Niemczyk S. The associations between body cell mass and nutritional and inflammatory markers in patients with chronic kidney disease and in subjects without kidney disease. J Ren Nutr. 2016;26(2):87‐92. doi:10.1053/j.jrn.2015.09.005
   Web of Science ®Google Scholar
• Grossmann M, Ng Tang Fui M, Cheung AS. Late-onset hypogonadism: metabolic impact. Andrology. 2019. doi:10.1111/andr.12705
   Web of Science ®Google Scholar
• Cobo G, Cordeiro AC, Amparo FC, Amodeo C, Lindholm B, Carrero JJ. Visceral adipose tissue and leptin hyperproduction are associated with hypogonadism in men with chronic kidney disease. J Ren Nutr. 2017;27(4):243‐248. doi:10.1053/j.jrn.2017.01.023
   Web of Science ®Google Scholar
• Kelly DM, Jones TH. Testosterone: a metabolic hormone in health and disease. J Endocrinol. 2013;217(3):25‐45. doi:10.1530/JOE-12-0455
   Web of Science ®Google Scholar
• Gungor O, Kircelli F, Carrero JJ, et al. Endogenous testosterone and mortality in male hemodialysis patients: is it the result of aging? Clin J Am Soc Nephrol. 2010;5(11):2018‐2023. doi:10.2215/CJN.03600410
   Web of Science ®Google Scholar
• Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73(4):391‐398. doi:10.1038/sj.ki.5002585
   Web of Science ®Google Scholar
• Carrero JJ, Qureshi AR, Nakashima A, et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant. 2011;26(1):184‐190. doi:10.1093/ndt/gfq397
   Web of Science ®Google Scholar
• Chiang JM, Kaysen GA, Segal M, Chertow GM, Delgado C, Johansen KL. Low testosterone is associated with frailty, muscle wasting and physical dysfunction among men receiving hemodialysis: a longitudinal analysis. Nephrol Dial Transplant. 2019;34(5):802‐810. doi:10.1093/ndt/gfy252
   Web of Science ®Google Scholar
• Harada K, Suzuki S, Ishii H, et al. Impact of skeletal muscle mass on long-term adverse cardiovascular outcomes in patients with chronic kidney disease. Am J Cardiol. 2017;119(8):1275‐1280. doi:10.1016/j.amjcard.2017.01.003
   Web of Science ®Google Scholar
• Zhou Y, Hellberg M, Svensson P, Höglund P, Clyne N. Sarcopenia and relationships between muscle mass, measured glomerular filtration rate and physical function in patients with chronic kidney disease stages 3-5. Nephrol Dial Transplant. 2018;33(2):342‐348. doi:10.1093/ndt/gfw466
   Web of Science ®Google Scholar
• Watanabe H, Enoki Y, Maruyama T. Sarcopenia in chronic kidney disease: factors, mechanisms, and therapeutic interventions. Biol Pharm Bull. 2019;42(9):1437‐1445. doi:10.1248/bpb.b19-00513
   Web of Science ®Google Scholar
• Cigarrán S, Pousa M, Castro MJ, et al. Endogenous testosterone, muscle strength, and fat-free mass in men with chronic kidney disease. J Ren Nutr. 2013;23(5):89‐95. doi:10.1053/j.jrn.2012.08.007
   Web of Science ®Google Scholar
• Rymarz A, Matyjek A, Gomółka M, Niemczyk S. Lean tissue index and body cell mass can be predictors of low free testosterone levels in men on hemodialysis. J Ren Nutr. 2019;29(6):529‐535. doi:10.1053/j.jrn.2019.03.078
   Web of Science ®Google Scholar
• Amiri M, Ramezani Tehrani F, Rahmati M, et al. Low serum testosterone levels and the incidence of chronic kidney disease among male adults: a prospective population-based study. Andrology. 2020;8(3):575–582. doi:doi:10.1111/andr.1272831697870
   PubMed Web of Science ®Google Scholar
• Mouser JG, Loprinzi PD, Loenneke JP. The association between physiologic testosterone levels, lean mass, and fat mass in a nationally representative sample of men in the United States. Steroids. 2016;115:62‐66. doi:1016/j.steroids.2016.08.009
   Web of Science ®Google Scholar
• Supasyndh O, Satirapoj B, Aramwit P, et al. Effect of oral anabolic steroid on muscle strength and muscle growth in hemodialysis patients. Clin J Am Soc Nephrol. 2013;8(2):271‐279. doi:10.2215/CJN.00380112
   Web of Science ®Google Scholar